SBI Biotech is developing the novel therapeutic drugs in the pre-clinical stage for autoimmune diseases and cancers by targeting pDCs and B cells.

Recent News

08/28/2017

Our headquarter office is moved to Izumi Garden Tower 15F.

10/21/2016

SBI Biotech’s Licensed product, an Anti-ILT7 antibody (MEDI7734) has achieved a Developmental Milestone in a Phase I Clinical Trial[Written in Japanese]

04/19/2016

SBI Biotech’s Licensed product, an Anti-ILT7 antibody, has IND approval to initiate a Phase Ⅰ Clinical Trial(PDF/39KB)

03/15/2016

SBI Biotech’s Subsidiary Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase Ⅲ Studies and One Phase Ⅱ Study of RNAi-Based Therapeutics for Kidney and Eye Indications[Written in Japanese](PDF/154KB)

12/22/2015

Announcement of new director.[Written in Japanese](PDF/119KB)

03/30/2015

Announcement of change of top management.[Written in Japanese](PDF/84KB)

News Overview

  • SBI証券のNISA口座なら、国内株式手数料1年間0円
  • 先進医療だけでなく自由診療も実額補償の「がん保険!」
  • [MoneyLook]ペイオフ時代を乗り切る、資産を守る最強ツール!

 Back to top